Literature DB >> 10087501

Modelling of adrenoceptor ligand targets based on novel medium- or macro-sized fused nitrogen heterocyclic systems.

R Griffith1, J B Bremner.   

Abstract

Novel medium- and macro-sized heterocyclic compounds were assessed for their potential as subtype-selective adrenergic ligands. Their conformational flexibilities were investigated and their geometric shapes were compared to rigid lead compounds of known selectivity. In the case of alpha 1A selective antagonists, interesting potential targets for synthesis and evaluation were identified by 'opening up' various rings of the fused-ring lead compound 1 by shared-bond cleavage. For alpha 2 selective ligands, compound 6 was the lead compound and the possibility of mimicking the fused-ring system via intramolecular hydrogen bonding was investigated. None of the potential targets were closely enough related in this case to the lead compound to warrant synthesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10087501     DOI: 10.1023/a:1008087131806

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  9 in total

1.  A quantitative investigation of the transannular amine-ketone (N...C=O) interaction in medium-sized heterocycles.

Authors:  R Griffith; B F Yates; J B Bremner; S J Titmuss
Journal:  J Mol Graph Model       Date:  1997-04       Impact factor: 2.518

2.  Pharmacophore development for antagonists at alpha 1 adrenergic receptor subtypes.

Authors:  J B Bremner; B Coban; R Griffith
Journal:  J Comput Aided Mol Des       Date:  1996-12       Impact factor: 3.686

Review 3.  Pharmacological options in the treatment of benign prostatic hyperplasia.

Authors:  B Kenny; S Ballard; J Blagg; D Fox
Journal:  J Med Chem       Date:  1997-04-25       Impact factor: 7.446

4.  (8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist.

Authors:  R D Clark; D B Repke; A T Kilpatrick; C M Brown; A C MacKinnon; R U Clague; M Spedding
Journal:  J Med Chem       Date:  1989-09       Impact factor: 7.446

5.  Chimeras of alpha1-adrenergic receptor subtypes identify critical residues that modulate active state isomerization.

Authors:  J Hwa; R M Graham; D M Perez
Journal:  J Biol Chem       Date:  1996-04-05       Impact factor: 5.157

Review 6.  Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications.

Authors:  R R Ruffolo; W Bondinell; J P Hieble
Journal:  J Med Chem       Date:  1995-09-15       Impact factor: 7.446

Review 7.  Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.

Authors:  J P Hieble; W E Bondinell; R R Ruffolo
Journal:  J Med Chem       Date:  1995-09-01       Impact factor: 7.446

8.  A possible structural determinant of selectivity of boldine and derivatives for the alpha 1A-adrenoceptor subtype.

Authors:  Y Madrero; M Elorriaga; S Martinez; M A Noguera; B K Cassels; P D'Ocon; M D Ivorra
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

9.  Identification of alpha 1-adrenoceptor subtypes in the human prostatic urethra.

Authors:  N Taniguchi; Y Ukai; T Tanaka; J Yano; K Kimura; N Moriyama; K Kawabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1997-03       Impact factor: 3.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.